All news

Barclays upgrades Zimmer Biomet to hold rating

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Barclays upgraded Zimmer Biomet (NYSE:ZBH) to a hold rating, matching the broader analyst consensus. The medical device maker's recent earnings beat expectations, with adjusted earnings of $2.07 per share and revenue of $2.18 billion. The analyst target of

Read original source

ZBH company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.